EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Patient Preferences for Unresectable Hepatocellular Carcinoma Treatments: A Discrete-Choice Experiment

Daneng Li iD, Ruoding Tan, Sairy Hernandez, Norelle Reilly, Cooper Bussberg, Carol Mansfield

Cancers · 25.02.2023 · 15 (5) · 1470

DOI: 10.3390/cancers15051470 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 25.02.2023. Verfasst von Daneng Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Genentech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatments for unresectable hepatocellular carcinoma (HCC) have varying benefit-risk profiles. We elicited 200 US patients’ preferences for attributes associated with various first-line systemic treatments for unresectable HCC in a discrete-choice experiment (DCE) survey. Respondents answered nine DCE questions, each offering a choice between two hypothetical treatment profiles defined by six attributes with varying levels: overall survival (OS), months of maintained daily function, severity of palmar-plantar syndrome, severity of hypertension, risk of digestive-tract bleeding, and mode and frequency of administration. A random-parameters logit model was used to analyze the preference data. Patients regarded an additional 10 months of maintaining daily function without decline to be as important or more important than 10 additional months of OS, on average. Respondents valued avoiding moderate-to-severe palmar-plantar syndrome and hypertension more than extended OS. A respondent would require >10 additional months of OS (the greatest increase presented in the study) on average to offset the increased burden of adverse events. Patients with unresectable HCC prioritize avoiding adverse events that would severely impact their quality of life over mode and frequency of administration or digestive-tract bleeding risk. For some patients with unresectable HCC, maintaining daily functioning is as important or more important than the survival benefit of a treatment.

Schlagwörter

Stichwörter der Autor:innen

discrete choicehealth-related quality of lifestated preferencessurvival

Autor:innen und Institutionen

  • City of Hope Comprehensive Cancer Center, Duarte, CA 91010, USA.
  • Genentech, Inc., South San Francisco, CA 94080, USA.
  • RTI Health Solutions, Research Triangle Park, NC 27709, USA.

ORCID-Profile: Daneng Li

Förderung

  • Genentech

Zitieren

APA

Li, D., Tan, R., Hernandez, S., Reilly, N., Bussberg, C., & Mansfield, C. (2023). Patient Preferences for Unresectable Hepatocellular Carcinoma Treatments: A Discrete-Choice Experiment. Cancers, 15(5), 1470. https://doi.org/10.3390/cancers15051470

Vancouver

Li D, Tan R, Hernandez S, Reilly N, Bussberg C, Mansfield C. Patient Preferences for Unresectable Hepatocellular Carcinoma Treatments: A Discrete-Choice Experiment. Cancers. 2023;15(5):1470. doi:10.3390/cancers15051470

BibTeX
@article{Li2023,
  author = {Li, Daneng and Tan, Ruoding and Hernandez, Sairy and Reilly, Norelle and Bussberg, Cooper and Mansfield, Carol},
  title = {Patient Preferences for Unresectable Hepatocellular Carcinoma Treatments: A Discrete-Choice Experiment},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {5},
  pages = {1470},
  doi = {10.3390/cancers15051470}
}
Kostenlos starten →